97 related articles for article (PubMed ID: 19683286)
21. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study.
Arai Y; Akaza H; Deguchi T; Fujisawa M; Hayashi M; Hirao Y; Kanetake H; Naito S; Namiki M; Tachibana M; Usami M; Ohashi Y
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1385-96. PubMed ID: 18491137
[TBL] [Abstract][Full Text] [Related]
23. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma.
Sciarra A; Di Silverio F
Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450
[TBL] [Abstract][Full Text] [Related]
24. The patient's choice of androgen-deprivation therapy in locally advanced prostate cancer: bicalutamide, a gonadotrophin-releasing hormone analogue or orchidectomy.
Nyman CR; Andersen JT; Lodding P; Sandin T; Varenhorst E
BJU Int; 2005 Nov; 96(7):1014-8. PubMed ID: 16225519
[TBL] [Abstract][Full Text] [Related]
25. [Locally advanced prostate cancer: definition, prognosis and treatment].
Plantade A; Massard C; de Crevoisier R; Fizazi K
Bull Cancer; 2007 Jul; 94(7 Suppl):F50-61. PubMed ID: 17845994
[TBL] [Abstract][Full Text] [Related]
26. Etoricoxib and intermittent androgen deprivation therapy in patients with biochemical progression after radical prostatectomy.
Di Silverio F; Sciarra A; Gentile V
Urology; 2008 May; 71(5):947-51. PubMed ID: 18279940
[TBL] [Abstract][Full Text] [Related]
27. Editorial comment to Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation.
Yoshida T
Int J Urol; 2013 Jul; 20(7):714-5. PubMed ID: 23216631
[No Abstract] [Full Text] [Related]
28. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
[TBL] [Abstract][Full Text] [Related]
29. Bicalutamide causes heart failure in an elderly patient with prostate cancer.
Guirguis K
Expert Opin Drug Saf; 2016; 15(3):297-302. PubMed ID: 26745594
[TBL] [Abstract][Full Text] [Related]
30. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study.
Thomsen FB; Brasso K; Christensen IJ; Johansson JE; Angelsen A; Tammela TL; Iversen P;
Eur J Cancer; 2015 Jul; 51(10):1283-92. PubMed ID: 25892647
[TBL] [Abstract][Full Text] [Related]
31. [The role of bicalutamide in the treatment of prostate cancer].
Stav SY; Segal G
Harefuah; 2002 Apr; 141(4):379-83, 408, 407. PubMed ID: 12017896
[TBL] [Abstract][Full Text] [Related]
32. Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma.
Chodak G; Sharifi R; Kasimis B; Block NL; Macramalla E; Kennealey GT
Urology; 1995 Dec; 46(6):849-55. PubMed ID: 7502428
[TBL] [Abstract][Full Text] [Related]
33. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
[TBL] [Abstract][Full Text] [Related]
34. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
[TBL] [Abstract][Full Text] [Related]
35. [Bicalutamide].
Taéron C
Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
[No Abstract] [Full Text] [Related]
36. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
37. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
[TBL] [Abstract][Full Text] [Related]
38. Bicalutamide with radiotherapy for prostate cancer.
Brower V
Lancet Oncol; 2017 Mar; 18(3):e141. PubMed ID: 28190764
[No Abstract] [Full Text] [Related]
39. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
[TBL] [Abstract][Full Text] [Related]
40. High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy.
Haller AC; Tan W; Payne-Ondracek R; Underwood W; Tian L; Morrison C; Li F
Prostate; 2014 May; 74(5):509-19. PubMed ID: 24375440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]